OncRef

Clinical Trial: NCT02008227

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2019-12-20

Study Overview

Brief Summary

This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

Official Title

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Atezolizumab
  • Drug: Docetaxel

Other Study ID Numbers

  • GO28915
  • 2013-003331-30

Start Date (Actual)

2014-03-11

Primary Completion Date (Actual)

2016-07-07

Study Completion Date (Actual)

2019-01-09

Enrollment (Actual)

1225

Study Type

Interventional

Phase

Phase 3